Skip to main content

Advertisement

SpringerLink
Log in

Kampo medicine “Dai-kenchu-to” prevents CPT-11-induced small-intestinal injury in rats

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

The key anticancer agent, CPT-11 (irinotecan hydrochloride), induces severe diarrhea clinically. We investigated the effect of a Kampo medicine, Dai-kenchu-to (DKT), on CPT-11-induced intestinal injuries in rats.

Methods

Twenty-four male Wistar rats were divided into three groups: a control group; a CPT-11 group, given CPT-11 150 mg/kg intraperitoneally for 2 days; and a DKT group, given DKT 300 mg/kg orally for 5 days with CPT-11 150 mg/kg intraperitoneally on days 4 and 5. The rats were killed on day 6.

Results

Interleukin (IL)-1β, IL-12, interferon (IFN)-γ, and tumor necrosis factor-α expression in the small intestine of the CPT-11 group was significantly higher than that of the control group. Interleukin-1β and IFN-γ expression was improved significantly by DKT (P < 0.05). The number and height of jejuna villi, injury score, and apoptosis index in the CPT-11 group were improved significantly by DKT (P < 0.05).

Conclusions

DKT suppressed CPT-11 induced inflammatory cytokines and apoptosis in the intestinal mucosa and maintained the mucosal integrity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol. 1993;11:909–13.

    PubMed  CAS  Google Scholar 

  2. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004;22:2849–55.

    Article  PubMed  CAS  Google Scholar 

  3. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol. 1990;8:1907–12.

    PubMed  CAS  Google Scholar 

  4. Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40:295–300.

    Article  PubMed  CAS  Google Scholar 

  5. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996;56:3752–7.

    PubMed  CAS  Google Scholar 

  6. Tallman MN, Miles KK, Kessler FK, Nielsen JN, Tian X, Ritter JK, et al. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats. J Pharmacol Exp Ther. 2007;320:29–37.

    Article  PubMed  CAS  Google Scholar 

  7. Onoue M, Kurita A, Kado S, Matsumoto T, Kaneda N, Uchida K, et al. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats. Cancer Chemother Pharmacol. 2008;61:595–605.

    Article  PubMed  CAS  Google Scholar 

  8. Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, et al. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev. 2004;30:555–62.

    Article  PubMed  CAS  Google Scholar 

  9. Itoh T, Yamakawa J, Mai M, Yamaguchi N, Kanda T. The effect of the herbal medicine Dai-kenchu-to on post-operative ileus. J Int Med Res. 2002;30:428–32.

    PubMed  CAS  Google Scholar 

  10. Satoh K, Kase Y, Hayakawa T, Murata P, Ishige A, Sasaki H. Dai-kenchu-to enhances accelerated small intestinal movement. Biol Pharm Bull. 2001;24:1122–6.

    Article  PubMed  CAS  Google Scholar 

  11. Yoshikawa K, Kurita N, Higashijima J, Miyatani T, Miyamoto H, Nishioka M, et al. Kampo medicine “Dai-kenchu-to” prevents bacterial translocation in rats. Dig Dis Sci. 2008;53:1824–31.

    Article  PubMed  Google Scholar 

  12. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol. 2003;18:1095–100.

    Article  PubMed  CAS  Google Scholar 

  13. Fukuda H, Chen C, Mantyh C, Ludwig K, Pappas TN, Takahashi T. The herbal medicine, Dai-kenchu-to, accelerates delayed gastrointestinal transit after the operation in rats. J Surg Res. 2006;131:290–5.

    Article  PubMed  Google Scholar 

  14. Gurbuz AT, Kunzelman J, Ratzer EE. Supplemental dietary arginine accelerates intestinal mucosal regeneration and enhances bacterial clearance following radiation enteritis in rats. J Surg Res. 1998;74:149–54.

    Article  PubMed  CAS  Google Scholar 

  15. Demirer S, Aydintug S, Aslim B, Kepenekci I, Sengül N, Evirgen O, et al. Effects of probiotics on radiation-induced intestinal injury in rats. Nutrition. 2006;22:179–86.

    Article  PubMed  CAS  Google Scholar 

  16. Iskit SH, Tugtepe H, Ayyildiz SH, Kotiloglu E, Dagli TE, Yeğen BC. Epidermal growth factor and bombesin act synergistically to support intestinal adaptation in rats with massive small bowel resection. Pediatr Surg Int. 2005;21:436–40.

    Article  PubMed  Google Scholar 

  17. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg. 1970;101:478–83.

    Article  PubMed  CAS  Google Scholar 

  18. Hang CH, Shi JX, Sun BW, Li JS. Apoptosis and functional changes of dipeptide transporter in the rat small intestine after traumatic brain injury. J Surg Res. 2006;137:53–60.

    Article  PubMed  Google Scholar 

  19. Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst. 1995;87:1876–83.

    Article  PubMed  CAS  Google Scholar 

  20. Kase Y, Hayakawa T, Aburada M, Komatsu Y, Kamataki T. Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn J Pharmacol. 1997;75:407–13.

    Article  PubMed  CAS  Google Scholar 

  21. Bowen JM, Stringer AM, Gibson RJ, Yeoh AS, Hannam S, Keefe DM. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther. 2007;6:1449–54.

    Article  PubMed  Google Scholar 

  22. Melo ML, Brito GA, Soares RC, Carvalho SB, Silva JV, Soares PM, et al. Role of cytokines (TNFα, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol. 2008;61:775–84.

    Article  PubMed  CAS  Google Scholar 

  23. Torisu M, Murakami H, Akbar F, Matsui H, Hiasa Y, Matsuura B, et al. Protective role of interleukin-10-producing regulatory dendritic cells against murine autoimmune gastritis. J Gastroenterol. 2008;43:100–7.

    Article  PubMed  CAS  Google Scholar 

  24. Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol. 2009;44:26–46.

    Article  PubMed  Google Scholar 

  25. Tagawa M. Cytokine therapy for cancer. Curr Pharm Des. 2006;6:681–99.

    Article  Google Scholar 

  26. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–147.

    PubMed  CAS  Google Scholar 

  27. Xing Z, Wang J. Consideration of cytokines as therapeutics agents or targets. Curr Pharm Des. 2000;6:599–611.

    Article  PubMed  CAS  Google Scholar 

  28. Hu ZP, Yang XX, Chan SY, Xu AL, Duan W, Zhu YZ, et al. St. John’s wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol Appl Pharmacol. 2006;216:225–37.

    Article  PubMed  CAS  Google Scholar 

  29. Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev. 2007;33:448–60.

    Article  PubMed  CAS  Google Scholar 

  30. Gibson RJ, Bowen JM, Keefe DM. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer. 2005;116:464–70.

    Article  PubMed  CAS  Google Scholar 

  31. Xue H, Sawyer MB, Field CJ, Dieleman LA, Murray D, Baracos VE. Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor. J Nutr. 2008;138:740–6.

    PubMed  CAS  Google Scholar 

  32. Endo S, Nishida T, Nishikawa K, Nakajima K, Hasegawa J, Kitagawa T, et al. Dai-kenchu-to, a Chinese herbal medicine, improves stasis of patients with total gastrectomy and jejunal pouch interposition. Am J Surg. 2006;192:9–13.

    Article  PubMed  Google Scholar 

  33. Sato Y, Inoue S, Katagiri F, Itoh H, Takeyama M. Effects of pirenzepine on Dai-kenchu-to-induced elevation of the plasma neuropeptide levels in humans. Biol Pharm Bull. 2006;29:166–71.

    Article  PubMed  CAS  Google Scholar 

  34. Murata P, Kase Y, Ishige A, Sasaki H, Kurosawa S, Nakamura T. The herbal medicine Dai-kenchu-to and one of its active components [6]-shogaol increase intestinal blood flow in rats. Life Sci. 2002;70:2061–70.

    Article  PubMed  CAS  Google Scholar 

  35. Kono T, Koseki T, Chiba S, Ebisawa Y, Chisato N, Iwamoto J. Colonic vascular conductance increased by Daikenchuto via calcitonin gene-related peptide and receptor-activity modifying protein 1. J Surg Res. 2008;150:78–84.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Surgery, The University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan

    Motoya Chikakiyo, Mitsuo Shimada, Toshihiro Nakao, Jun Higashijima, Kozo Yoshikawa, Masanori Nishioka, Takashi Iwata & Nobuhiro Kurita

Authors
  1. Motoya Chikakiyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsuo Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshihiro Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Higashijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kozo Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masanori Nishioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takashi Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobuhiro Kurita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitsuo Shimada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chikakiyo, M., Shimada, M., Nakao, T. et al. Kampo medicine “Dai-kenchu-to” prevents CPT-11-induced small-intestinal injury in rats. Surg Today 42, 60–67 (2012). https://doi.org/10.1007/s00595-011-0014-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-011-0014-7

Keywords

Search

Navigation